アテローム性動脈硬化プラーク細胞のマッピングが将来の脳卒中や心臓発作のリスクを予測する可能性(Mapping of atherosclerotic plaque cells may predict future risk of stroke or heart attack)

ad

2024-11-20 カロリンスカ研究所(KI)

カロリンスカ研究所の研究者は、動脈硬化性プラーク内の細胞構成が遺伝的要因によって影響を受けることを明らかにしました。この発見は、将来的な脳卒中や心臓発作のリスク評価や治療法の改善に寄与する可能性があります。研究チームは、患者の遺伝情報に基づき、プラーク内の平滑筋細胞の構成に違いがあることを発見し、これにより患者を3つのリスクグループに分類しました。この知見は、AIや最新の診断技術と組み合わせることで、より精度の高いリスク評価や治療法の開発に繋がると期待されています。

<関連情報>

アテロームのトランスクリプトミクスがARNTLを平滑筋細胞制御因子として同定し、臨床データおよび遺伝子データとともにリスク層別化を改善する Atheroma transcriptomics identifies ARNTL as a smooth muscle cell regulator and with clinical and genetic data improves risk stratification

Sampath Narayanan, Sofija Vuckovic, Otto Bergman, Robert Wirka, Jose Verdezoto Mosquera, Qiao Sen Chen, Damiano Baldassarre, Elena Tremoli, Fabrizio Veglia, Mariette Lengquist …
European Heart Journal  Published:18 November 2024
DOI:https://doi.org/10.1093/eurheartj/ehae768

アテローム性動脈硬化プラーク細胞のマッピングが将来の脳卒中や心臓発作のリスクを予測する可能性(Mapping of atherosclerotic plaque cells may predict future risk of stroke or heart attack)

Structured Graphical Abstract
An overview of the scientific questions, workflow design, and main findings of the study. CAD, coronary artery disease; GWAS, genome-wide association study; scRNAseq, single cell RNA sequencing; SMC, smooth muscle cell; SNP, single nucleotide polymorphism.

Abstract

Background and Aims
The role of vascular smooth muscle cells (SMCs) in atherosclerosis has evolved to indicate causal genetic links with the disease. Single cell RNA sequencing (scRNAseq) studies have identified multiple cell populations of mesenchymal origin within atherosclerotic lesions, including various SMC sub-phenotypes, but it is unknown how they relate to patient clinical parameters and genetics. Here, mesenchymal cell populations in atherosclerotic plaques were correlated with major coronary artery disease (CAD) genetic variants and functional analyses performed to identify SMC markers involved in the disease.

Methods
Bioinformatic deconvolution was done on bulk microarrays from carotid plaques in the Biobank of Karolinska Endarterectomies (BiKE, n = 125) using public plaque scRNAseq data and associated with patient clinical data and follow-up information. BiKE patients were clustered based on the deconvoluted cell fractions. Quantitative trait loci (QTLs) analyses were performed to predict the effect of CAD associated genetic variants on mesenchymal cell fractions (cfQTLs) and gene expression (eQTLs) in plaques.

Results
Lesions from symptomatic patients had higher fractions of Type 1 macrophages and pericytes, but lower fractions of classical and modulated SMCs compared with asymptomatic ones, particularly females. Presence of diabetes or statin treatment did not affect the cell fraction distribution. Clustering based on plaque cell fractions, revealed three patient groups, with relative differences in their stability profiles and associations to stroke, even during long-term follow-up. Several single nucleotide polymorphisms associated with plaque mesenchymal cell fractions, upstream of the circadian rhythm gene ARNTL were identified. In vitro silencing of ARNTL in human carotid SMCs increased the expression of contractile markers and attenuated cell proliferation.

Conclusions
This study shows the potential of combining scRNAseq data with vertically integrated clinical, genetic, and transcriptomic data from a large biobank of human plaques, for refinement of patient vulnerability and risk prediction stratification. The study revealed novel CAD-associated variants that may be functionally linked to SMCs in atherosclerotic plaques. Specifically, variants in the ARNTL gene may influence SMC ratios and function, and its role as a regulator of SMC proliferation should be further investigated.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました